Business
Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”
HOUSTON, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing
About this update from Marker Therapeutics, Inc.
[{"type":"text","content":"HOUSTON, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, announced today that the Company’s management team will participate in Biotech Showcase and present at the 19th Annual Non-Dilutive Funding Summit. Both events will be held in-person and are scheduled alongside the J.P. Morgan 42nd Annual Healthcare Conference 2024. Details of the events are as follows: Event:Biotech ShowcaseDate:January 8-10, 2024Location:Hilton San Francisco Union SquareRegistration:https://informaconnect.com/biotech-showcase/registration-options/ Event:The 19thAnnual Non-Dilutive Funding SummitDate:January 10, 2024Location:Marines’ Memorial Club & Hotel, San FranciscoWebsite:https://freemindgroup.com/19th-annual-non-dilutive-funding-summit/ Marker was awarded 2023 FreeMind Elite honoree, a group of FreeMind Group clients that are selected annually and honored for their achievements in pursuing non-dilutive funding. To date, Marker has secured more than $17 million in non-dilutive funding from various grant agencies, including FDA, NIH and Cancer Prevention & Research Institute of Texas (CPRIT). As part of the award announcement, Dr. Juan Vera, President and CEO of Marker Therapeutics, will give a presentation at the 19th Annual Non-Dilutive Funding Summit. During J.P. Morgan week, members of the Marker management team will conduct one-on-one meetings with registered investors, showcasing the Company’s business and clinical development, recent achievements, and anticipated milestones. About Marker Therapeutics, Inc.Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The T cell therapy technology developed by Marker is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e., tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient’s immune system to produce broad spectrum a...